- Trials with a EudraCT protocol (304)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
304 result(s) found for: Lymphatic Diseases AND Lymphoma AND Lymphomas.
Displaying page 1 of 16.
| EudraCT Number: 2016-002972-29 | Sponsor Protocol Number: CART19-BE-01 | Start Date*: 2017-05-16 | ||||||||||||||||||||||||||
| Sponsor Name:IDIBAPS | ||||||||||||||||||||||||||||
| Full Title: Pilot study on the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (... | ||||||||||||||||||||||||||||
| Medical condition: Patients with leukemia or lymphoma refractory to therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2012-005580-27 | Sponsor Protocol Number: ONC-2011-005 | Start Date*: 2013-04-06 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:ISTITUTO CLINICO HUMANITAS | ||||||||||||||||||||||||||||||||||||||
| Full Title: MULTI-CENTER, PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING REDUCED INTENSITY CONDITIONING (RIC) REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE,... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with lymphomas (any histology) relapsed after high dose chemotherapy and in complete remission or partial remission after the last CT line | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-003560-31 | Sponsor Protocol Number: UKM18_0021 | Start Date*: 2020-01-29 | |||||||||||
| Sponsor Name:Universitätsklinikum Münster | |||||||||||||
| Full Title: A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
| Medical condition: diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001058-16 | Sponsor Protocol Number: NLG-LBC-07 | Start Date*: 2017-02-15 | |||||||||||
| Sponsor Name:Nordic Lymphoma Group | |||||||||||||
| Full Title: A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma. | |||||||||||||
| Medical condition: Relapsed/refractory diffuse large B-cell lymphoma, including transformed low grade lymphoma. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002251-26 | Sponsor Protocol Number: CL1-078454-018 | Start Date*: 2014-09-08 | |||||||||||||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||||||||||||
| Full Title: Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study | |||||||||||||||||||||||
| Medical condition: Hodgkin's Disease (HD) , Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2012-001597-29 | Sponsor Protocol Number: HEM2012ZrOR001 | Start Date*: 2012-07-10 | |||||||||||
| Sponsor Name:VU University Medical Center | |||||||||||||
| Full Title: Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma patients | |||||||||||||
| Medical condition: Diffuse large B cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003256-22 | Sponsor Protocol Number: UKM17_0017 | Start Date*: 2018-03-22 | |||||||||||
| Sponsor Name:Universitätsklinikum Münster | |||||||||||||
| Full Title: Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma | |||||||||||||
| Medical condition: diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-003769-14 | Sponsor Protocol Number: FIL_DLCL10 | Start Date*: 2012-09-27 | |||||||||||
| Sponsor Name:Fondazione Italiana Linfomi ONLUS | |||||||||||||
| Full Title: R-CHOP-14 or R-CHOP-21 & consolidation PET–oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients with low risk profile according to age-adjusted IPI (0 with bulky or 1) | |||||||||||||
| Medical condition: Patient with diffuse large B cell lymphoma (DLBCL) with low risk profile according to age-adjusted IPI (0 with bulky or 1) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003658-22 | Sponsor Protocol Number: XmAb13676-03 | Start Date*: 2022-09-21 | |||||||||||
| Sponsor Name:Xencor, Inc. | |||||||||||||
| Full Title: A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb®13676 (Plamotamab) Combined with Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide i... | |||||||||||||
| Medical condition: Relapsed or refractory diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001421-24 | Sponsor Protocol Number: FIL_R-BENDAFRAIL | Start Date*: 2012-02-02 | |||||||||||
| Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
| Full Title: Rituximab plus Bendamustine as front line treatment in frail elderly (≥70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana L... | |||||||||||||
| Medical condition: Patients with diffuse large B-cell non-Hodgkin’s lymphoma in frail elderly (≥70 years) patients | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-004225-24 | Sponsor Protocol Number: PCI-32765CAN3001 | Start Date*: 2013-01-15 | ||||||||||||||||||||||||||
| Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
| Full Title: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | ||||||||||||||||||||||||||||
| Medical condition: chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) SE (Completed) BE (Trial now transitioned) IE (Completed) PT (Trial now transitioned) HU (Completed) NL (Ongoing) GR (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2018-003465-33 | Sponsor Protocol Number: PLRG12 | Start Date*: 2019-04-24 | ||||||||||||||||
| Sponsor Name:Polish Lymphoma Research Group - PLRG | ||||||||||||||||||
| Full Title: Acalabrutinib in CLL and MCL patients subjected to allogeneic hematopoietic stem cell transplantation (alloSCT). | ||||||||||||||||||
| Medical condition: Mantle Cell Lymmphoma (MCL) Chronic Lymphocytic Leukaemia (CLL) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: PL (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-003230-17 | Sponsor Protocol Number: MO28457 | Start Date*: 2013-02-14 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
| Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DI... | |||||||||||||
| Medical condition: The target population will consist of adults with previously untreated CD20+ DLBCL or CD20+ follicular NHL Grade 1, 2 or 3a, according to the WHO classification system. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) NL (Completed) IT (Completed) PT (Completed) SE (Completed) AT (Completed) DK (Completed) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000669-19 | Sponsor Protocol Number: MO28107 | Start Date*: 2012-07-30 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTRE, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN COMBINATION WITH CHOP ... | |||||||||||||
| Medical condition: Adult patients aged 18-80 years with previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) FI (Completed) NL (Completed) GR (Completed) GB (Completed) IT (Completed) IE (Completed) FR (Completed) BE (Completed) BG (Completed) PT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-011433-27 | Sponsor Protocol Number: ML22489 | Start Date*: 2009-11-04 | |||||||||||
| Sponsor Name:Roche Romania SRL | |||||||||||||
| Full Title: A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: RO (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004628-31 | Sponsor Protocol Number: FIL_V-RBAC | Start Date*: 2018-05-15 | |||||||||||
| Sponsor Name:Fondazione Italiana Linfomi ONLUS | |||||||||||||
| Full Title: Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) | |||||||||||||
| Medical condition: Mantle Cell Lymphoma in elderly patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004937-26 | Sponsor Protocol Number: GELLC-7 | Start Date*: 2017-07-13 | ||||||||||||||||
| Sponsor Name:Fundación PETHEMA | ||||||||||||||||||
| Full Title: A multicenter, non-randomized, open label study to evaluate the efficacy and security of Ibrutinib followed by ofatumumab consolidation in previously untreated patients with Chronic Lymphocytic Leu... | ||||||||||||||||||
| Medical condition: Chronic Lymphocytic Leukemia or Lymphocytic Small Cell Lymphoma without previous treatment | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-004707-32 | Sponsor Protocol Number: IMPROVE(PS-CLL-002) | Start Date*: 2017-05-10 | |||||||||||
| Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
| Full Title: A Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax through a MRD-guided Approach in Relapsed/Refractory ... | |||||||||||||
| Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-000159-14 | Sponsor Protocol Number: CLL1818 | Start Date*: 2019-09-17 | ||||||||||||||||||||||||||
| Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||||||||||||
| Full Title: Prospective study on the incidence of hepatitis B virus reactivation in untreated patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive treated with Rituximab, Chemot... | ||||||||||||||||||||||||||||
| Medical condition: Chronic lymphocytic leukemia is a neoplasm of the lymphatic system characterized by an accumulation of B lymphocytes in peripheral blood, bone marrow and lymphatic organs. Diffuse Large Cell B Lymp... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2021-003936-10 | Sponsor Protocol Number: D8220C00027 | Start Date*: 2022-06-28 | ||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||
| Full Title: MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia o... | ||||||||||||||||||
| Medical condition: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) PL (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
